Announcements Trials
Browse Landscape

Status

No longer available 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 44Observational 7Expanded_access 4

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Melanoma 3Small Cell Lung Carcinoma 1Skin Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × dabrafenib × Clear all
NCT04489433 2025-12-18

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Novartis

No longer available
Dermatologic

Melanoma

NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04544202 2024-11-12

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Novartis

No longer available
Dermatologic

Melanoma, Skin Neoplasms

NCT02416232 2017-08-15

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

GlaxoSmithKline

No longer available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡